This week's episode focuses on early-stage and locally advanced non-small cell lung cancer - staging, pathology, local and systemic therapy. Before we start, the usual caveat: the treatment landscape of NSCLC is changing FAST, which is exciting, but know that the boards run a few years behind. The big shifts since our last episode are the move to 9th-edition TNM staging and the arrival of four different perioperative chemo+immunotherapy regimens. Shout out to Dr. Bharathi Muthusamy for reviewing this episode to keep us current for 2026!

Today’s episode is focusing on what you need to know regarding myelodysplastic syndrome (MDS). This will include the high yield facts on risk factors, diagnostic work-up, staging and treatment of MDS, we were overdue do this this topic, last done in 2022.

This week’s episode will be focusing on syndromes of iron overload. We will go over all important details on hemochromatosis and other related diseases. We last covered this topic in 2023.

This week’s episode will be focusing on how to approach a newly diagnosed malignancy, biopsy, staging, patient considerations ect.

This week’s episode will be focusing on how to transition well into heme/onc fellowship including differences from residency, tips for surviving, wellness, resources & more.

This week’s episode will be focusing on Diffuse Large B-Cell Lymphoma (DLBCL). We will go all the important details on this aggressive NHL which can be highly curable. We have some new changes since we last covered this topic in 2022 including a new category 1 option for advanced DLBCL

This week’s episode we are back with our very special guest, friend and colleague Dr Laura Vater joining us to talk about wellness in oncology, and burnout prevention tips.

This week’s episode we have a very special guest, friend and colleague Dr. Laura Vater joining us to talk about one of the biggest transitions in medicine—moving from fellow to attending.

Dr Vater is a GI oncologist at IU, writer, and speaker. She focuses on the dignity of patients and clinicians, and strives to keep healthcare human. 

This week’s episode will be focusing on an ASCO 2026 Plenary abstract, SARC 041. SARC041 is the first positive phase 3 randomized controlled trial of a CDK4/6 inhibitor in advanced dedifferentiated liposarcoma (DDLPS), demonstrating that abemaciclib significantly improves progression-free survival compared to placebo. 

Today we are recapping exciting GU data presented at the 2026 ASCO Annual Meeting in bladder cancer, kidney cancer, and prostate cancer.